HVEM Gene Polymorphisms Are Associated with Sporadic Breast Cancer in Chinese Women

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Li, Dalin ^a   Fu, Zhenkun ^a   Chen, Shuang ^a   Yuan, Weiguang ^a   Liu, Yanhong ^a   Li, Liqun ^a   Pang, Da ^a   Li, Dianjun ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; HERPESVIRUS ENTRY MEDIATOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; HVEM GENE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SPORADIC BREAST CANCER;

ADULT; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84881568324     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071040     Document Type: Article

References (26)

1. Kroczek RA, Mages HW, Hutloff A, (2004) Emerging paradigms of T-cell co-stimulation. Curr. Opin. Immunol. 16: 321-327.
2. Kwon BS, Tan KB, Ni J, Oh KO, Lee ZH, et al. (1997) A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem. 272: 14272-14276.
3. Spear PG, (2004) Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol. 6: 401-410.
4. Montgomery RI, Warner MS, Lum BJ, Spear PG, (1996) Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87: 427-436.
5. Carfi A, Willis SH, Whitbeck JC, Krummenacher C, Cohen GH, et al. (2001) Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol Cell. 8: 169-179.
6. Cai G, Freeman GJ, (2009) The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol. Rev. 229: 244-258.
7. Murphy TL, Murphy KM, (2010) Slow down and survive: enigmatic immunoregulation by BTLA and HVEM. Annu. Rev. Immunol. 28: 389-411.
8. Del Rio ML, Lucas CL, Buhler L, Rayat G, Rodriguez-Barbosa JI, (2010) HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. J. Leukoc. Biol. 87: 223-235.
9. Tamada K, Shimozaki K, Chapoval AI, Zhu G, Sica G, et al. (2000) Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat. Med. 6: 283-289.
10. Cohavy O, Zhou J, Granger SW, Ware CF, Targan SR, (2004) LIGHT expression by mucosal T cells may regulate IFN-γ expression in the intestine. J. Immunol. 173: 251-258.
11. Cheung TC, Steinberg MW, Oborne LM, Macauley MG, Fukuyama S, et al. (2009) Unconventional ligand activation of herpesvirus entry mediator signals cell survival. Proc. Natl. Acad. Sci. USA 106: 6244-6249.
12. Murphy KM, Nelson CA, Sedy JR, (2006) Balancing co-stimulation and inhibition with BTLA and HVEM. Nat. Rev. Immunol. 6: 671-681.
13. Barreiro LB, Laval G, Quach H, Patin E, Quintana-Murci L, (2008) Natural selection has driven population differentiation in modern humans. Nature Genetics 40: 340-345.
14. Wang J, Pang GS, Chong SS, Lee CG, (2012) SNP Web Resources and Their Potential Applications in Personalized Medicine. Curr Drug Metab. 13: 978-990.
15. Struyf F, Posavad CM, Keyaerts E, Van Ranst M, Corey L, et al. (2002) Search for polymorphisms in the genes for herpesvirus entry mediator, nectin-1, and nectin-2 in immune seronegative individuals. J Infect Dis. 185: 36-44.
16. Chemnitz JM, Lanfranco AR, Braunstein I, Riley JL, (2006) B and T lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs. J Immunol 176: 6603-6614.
17. Deanne MC, Lino CG, Irene T, Kelly ML, Dan E, et al. (2005) Attenuating Lymphocyte Activity: THE CRYSTAL STRUCTURE OF THE BTLA-HVEM COMPLEX. J Biol Chem. 280: 39553-61.
18. Tao R, Wang LQ, Kenneth MM, Christopher CF, Wayne WH, (2008) Regulatory T Cell Expression of Herpesvirus Entry Mediator Suppresses the Function of B and T Lymphocyte Attenuator-Positive Effector T Cells. J Immunol. 180: 6649-6655.
19. Fu Z, Li D, Jiang W, Wang L, Zhang J, et al. (2010) Association of BTLA gene polymorphisms with the risk of malignant breast cancer in Chinese women of Heilongjiang Province. Breast Cancer Res Treat. 120: 195-202.
20. Jonsson JJ, Foresman MD, Wilson N, McIvor RS, (1992) Intron requirement for expression of the human purine nucleoside phosphorylase gene. Nucleic Acids Res 20: 3191-3198.
21. Baralle D, Baralle M, (2005) Splicing in action: assessing disease causing sequence changes. J Med Genet. 42: 737-748.
22. Kim HJ, Han W, Yi OV, Shin HC, Ahn SK, et al. (2011) Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype. Breast Cancer Res Treat. 130: 499-505.
23. Stendahl M, Ryden L, Nordenskjold B, Jonsson PE, Landberg G, et al. (2006) High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res. 12: 4614-4618.
24. Perez EA, Patel T, Moreno-Aspitia A, (2010) Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat. 121: 261-71.
25. Rudolph P, Alm P, Olsson H, Heidebrecht HJ, Ferno M, et al. (2001) Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. Hum Pathol. 32: 311-319.
26. Logullo AF, Lopes AB, Nonogaki S, Soares FA, Netto MM, et al. (2007) C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer. Oncol Rep. 18: 121-126.